Fundraising, advocacy continues as family of “Mighty Max” awaits Zolgensma funding application results
It has been a whirlwind 24 hours for the family of Fairview’s “Mighty Max”, but with Wednesday’s news of case-by-case funding for the gene replacement therapy drug Zolgensma here in Alberta settling in, the journey to ensure young Max gets his treatment continues.
The drug has been needed by two-year-old Max Sych, who suffers from Spinal Muscular Atrophy Type 2, which is a rare motor neuron disorder that can affect the muscles used for head and neck control, sitting, crawling, walking, and swallowing.
Health Minister Tyler Shandro said Wednesday the province would help cover the costs of the drug on a case-by-case basis, which prior to that announcement, would have come in at an estimated cost of $2.8 million CAD for the family.
FROM WEDNESDAY: Zolgensma to be funded on case-by-case basis in Alberta